Therapeutic @entity2332 for XXXX .

@entity1 @entity410 @entity1003 @entity1150 @entity281 @entity159 @entity2332
BACKGROUND: Our goal was to perform a systematic review of the literature on the use of therapeutic @entity2332 for @entity159 ( @entity159 ) and its impact on @entity410 control. METHODS: All articles from MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, Scopus, Cochrane Library, the International Clinical Trials Registry Platform (inception to May 2014), reference lists of relevant articles, and gray literature were searched. The strength of evidence was adjudicated by two independent reviewers, using both the Oxford and GRADE methodology. RESULTS: Overall, 13 studies were identified, with 10 manuscripts and 3 meeting abstracts. A total of 40 @entity1 were treated. The common target temperature was 33 degrees Celsius, sustained for a median 48 hours. @entity1 displayed a 62.5%, 15% and 22.5% rate of @entity410 cessation, @entity410 reduction, and failure of treatment respectively. External cooling was utilized in the majority of cases. @entity1150 , @entity1003 and @entity281 were the commonly reported complications. Two ongoing clinical trials were identified. CONCLUSIONS: Oxford level 4, GRADE D evidence exists to support the use of therapeutic @entity2332 to control @entity410 in @entity159 . Further prospective study is warranted.
